Last mentioned: Mar 18, 2026
STAT Analysis Released
Data confirms a 35% nosedive in Big Pharma antimicrobial R&D over the preceding 60 months.
Small Biotech Crisis
A wave of bankruptcies among small antibiotic developers highlights the 'broken market' for new treatments.
Market Exit Acceleration
Several large pharma entities announce the closure of infectious disease units to focus on chronic therapies.
Baseline Period
Major drugmakers maintain active antimicrobial pipelines before a steady five-year decline begins.
BioVersys AG reported its full-year 2025 financial results, highlighting significant clinical progress for its lead antimicrobial candidates and a stable cash position. The Swiss biotech successfully advanced its AlpE program into Phase 2b trials, reinforcing its leadership in the fight against multi-drug resistant infections.
A new analysis reveals a 35% decline in antimicrobial R&D by major pharmaceutical companies over the last five years, highlighting a deepening crisis in the fight against drug-resistant superbugs. The exodus of large-scale investment underscores the persistent lack of economic incentives for developing life-saving antibiotics.